ライフサイエンスコーパス: cinacalcet

1 n, an effect rectified with the calcimimetic cinacalcet.

2 d 238 of 1948 (12.2%) patients randomized to cinacalcet.

3 erparathyroidism with the calcimimetic agent cinacalcet.

4 ficantly more frequent in patients receiving cinacalcet.

5 etic etelcalcetide and the oral calcimimetic cinacalcet.

6 resence and absence of the calcimimetic drug cinacalcet.

7 parathyroidectomy, and 4866 (95.5%) received cinacalcet.

8 , which can be ameliorated by treatment with cinacalcet.

9 tal of 395 patients received once-daily oral cinacalcet (260 HD, 34 PD) or placebo (89 HD, 12 PD) tit

10 treatment were randomly assigned to receive cinacalcet (371 patients) or placebo (370 patients) for

11 Among patients randomized to cinacalcet, a >/=30% reduction in FGF23 between baseline

12 Cinacalcet, a CaSR positive allosteric modulator, decrea

13 In healthy volunteers, cinacalcet administration, fructose intake, or a single

14 Cinacalcet also significantly reduced serum calcium, pho

15 avenously and oral placebo (n = 340) or oral cinacalcet and IV placebo (n = 343) for 26 weeks.

16 Cinacalcet and NPS-2143 are allosteric CaSR activators a

17 This study investigated whether cinacalcet and NPS-2143 may rectify Ca(2+) i alterations

18 Cinacalcet and NPS-2143 rectified the Ca(2+) i responses

19 ein-coupled protomer at the same location as cinacalcet and other allosteric modulators.

20 f 343 patients (57.7%) randomized to receive cinacalcet and the 232 of 340 patients (68.2%) randomize

21 nal disease phase at the time of transplant, cinacalcet, and native vitamin D were used significantly

22 -fold more potent than the standard of care, cinacalcet, and reduced serum PTH levels in mice without

23 athyroid hormone; and nutritional vitamin D, cinacalcet, and warfarin treatments were associated with

24 ared with younger patients and the effect of cinacalcet appeared more pronounced in older patients.

25 Cinacalcet appears to be an effective drug for the treat

26 From nonrandomized studies, cinacalcet appears to be safe and effective for the trea

27 lues decreased 43 percent in those receiving cinacalcet but increased 9 percent in the placebo group

28 g an unadjusted intention-to-treat analysis, cinacalcet did not reduce the rate of clinical fracture.

29 n an unadjusted intention-to-treat analysis, cinacalcet did not significantly reduce the risk of deat

30 ld be more cost effective than cinacalcet if cinacalcet duration reached 14 months.

31 Cinacalcet effectively reduced parathyroid hormone level

32 firmed the efficacy of the oral calcimimetic cinacalcet for achieving long-term reductions in serum c

33 tal parathyroidectomy is more effective than cinacalcet for controlling hypercalcemia caused by persi

34 11 kidney transplant recipients treated with cinacalcet for hyperparathyroidism met inclusion criteri

35 Additionally, patients treated with cinacalcet for SHPT should undergo close surveillance fo

36 At 12 months, ten of 15 patients in the cinacalcet group and 15 of 15 patients in the parathyroi

37 ached in 938 of 1948 patients (48.2%) in the cinacalcet group and 952 of 1935 patients (49.2%) in the

38 rse events were digestive intolerance in the cinacalcet group and hypocalcemia in the parathyroidecto

39 phorus product declined by 15 percent in the cinacalcet group and remained unchanged in the placebo g

40 Forty-three percent of the cinacalcet group reached the primary end point, as compa

41 in the placebo group (relative hazard in the cinacalcet group vs. the placebo group, 0.93; 95% confid

42 f study-drug exposure was 21.2 months in the cinacalcet group, versus 17.5 months in the placebo grou

43 larger proportion of patients randomized to cinacalcet had >/=30% (68% versus 28%) reductions in FGF

44 Cinacalcet had comparable efficacy in HD and PD patients

45 The use of calcimimetic cinacalcet has been established to activate CaSR and nor

46 However, cinacalcet has limitations due to its high cLogP and pK(

47 The calcimimetic cinacalcet HCl acts on the calcium-sensing receptor to i

48 modialysis using data from the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events tr

49 d anilines as well as the bioactive compound Cinacalcet HCl.

50 and effectiveness of the calcimimetic agent cinacalcet hydrochloride.

51 Surgery would be more cost effective than cinacalcet if cinacalcet duration reached 14 months.

52 , subtotal parathyroidectomy was superior to cinacalcet in controlling hypercalcemia in these patient

53 d study evaluated the efficacy and safety of cinacalcet in hemodialysis (HD) and peritoneal dialysis

54 the use of etelcalcetide was not inferior to cinacalcet in reducing serum PTH concentrations over 26

55 identified studies evaluating treatment with cinacalcet in renal transplant recipients with hyperpara

56 There is limited experience with the use of cinacalcet in the treatment of persistent secondary hype

57 Cinacalcet lowers parathyroid hormone levels and improve

58 etics profile, and lacked the liabilities of cinacalcet, making it a highly differentiated precision

59 d that treatment with the calcimimetic agent cinacalcet might reduce the risk of death or nonfatal ca

60 otal, 30 patients were randomized to receive cinacalcet (n=15) or subtotal parathyroidectomy (n=15).

61 Cinacalcet offers a new therapeutic option for controlli

62 Etelcalcetide was noninferior to cinacalcet on the primary end point.

63 entified 5094 adults (age 18 y) treated with cinacalcet or parathyroidectomy for SHPT before receivin

64 ith secondary hyperparathyroidism to receive cinacalcet or placebo for </=64 months.

65 re undergoing hemodialysis to receive either cinacalcet or placebo.

66 ared with 138 patients (40.2%) randomized to cinacalcet (P = .001; difference in proportions, 12.2%;

67 nts prompting discontinuation of study drug, cinacalcet reduced the rate of clinical fracture by 16%-

68 Cinacalcet resulted in hypocalcemia in seven patients.

69 Treatment with cinacalcet significantly lowers serum FGF23.

70 fer (pH 7.4), and CaR-specific calcimimetic, cinacalcet, stimulated gastrin and acid secretion, where

71 lar Ca(2+)-sensing receptor (CaSR) activator cinacalcet that stimulates cAMP hydrolysis.

72 tomy, transplant, or provision of commercial cinacalcet), the relative hazard was 0.71 (95% CI, 0.58

73 18 renal allograft recipients who initiated cinacalcet therapy from 1 month to 23 years (median 3 ye

74 However, compared with patients treated with cinacalcet, those treated with parathyroidectomy had a l

75 loid phenethylamine or calcium-reducing drug cinacalcet to elicit different biological responses.

76 to analyze the effects of etelcalcetide and cinacalcet to lower plasma PTH levels in individuals on

77 sis of a randomized clinical trial comparing cinacalcet to placebo in addition to conventional therap

78 A systematic optimization of cinacalcet to reduce its cLogP and pK(a) yielded compoun

79 arathyroid hormone (PTH), IV vitamin D dose, cinacalcet use, and phosphate binder use.

80 yroid hormone, or C-reactive protein levels, cinacalcet use, or phosphate binder or calcitriol dose i

81 analysis, the relative hazard for fracture (cinacalcet versus placebo) was 0.89 (95% confidence inte

82 to determine the effects of the calcimimetic cinacalcet (versus placebo) on reducing serum FGF23 and

83 ong participants who remained untreated with cinacalcet, vitamin D sterols, or parathyroidectomy.

84 ng IV etelcalcetide vs oral placebo and oral cinacalcet vs IV placebo in 683 patients receiving hemod

85 Once-daily oral cinacalcet was effective in rapidly and safely reducing

86 During a 10-wk efficacy assessment phase, cinacalcet was more effective than control for PTH reduc

87 ks of treatment with either etelcalcetide or cinacalcet without regard to the degree of hyperphosphat

88 We tested the hypothesis that cinacalcet would reduce the rate of clinical fractures i